Table 1.
Mouse strain | Deficiency* | Outcome | References |
---|---|---|---|
AG129 | IFNα/βR and IFNγR (129 background) | Mortality DENV-2, DENV-3, DENV-4 | [40][67][74] |
AGB6 | IFNα/βR and IFNγR | Mortality DENV-2, DENV-4 | [75] |
A129 | IFNα/βR (129 background) | Mortality DENV-2 Survival DENV-4 | [47] [75] |
G129 | IFNγR in (129 background) | Survival DENV-2 | [41] |
IFNAR−/− | IFNα/βR | Mortality DENV-2 | [43] |
Mavs−/− | MAVS | Survival DENV-2, DENV-4 | [44][75] |
STAT1−/− | STAT1 | Mortality DENV-2 | [49] |
STAT2−/− | STAT2 | Survival DENV-2 | [49] |
STAT1−/−2−/− | STAT1 and STAT2 | Mortality DENV-2 | [49] |
STAT1−/−/AR | STAT1 and IFNα/βR | Mortality DENV-2 | [49] |
STAT1−/−/GR | STAT1 and IFNγR | Survival DENV-2 | [49] |
IRF3−/− | IRF3 | Survival DENV-2 | [48] |
IRF7−/− | IRF7 | Survival DENV-2 | [48] |
IRF3−/−7−/− | IRF3 and IRF7 | Survival DENV-2 | [48] |
HLAIIFNAR−/− | HLA-A*0201/Kb, A*1101/Kb, A*0101, B*0702, or DRB1*0101 transgenics and IFNα/βR | Not evaluated for mortality# | [52] |
LysM-Cre+/−IFNARfl/fl | IFNα/βRonly in macrophages | Morbidity, some mortalityDENV-2 | [66] |
CD11c-Cre+/−IFNARfl/fl | IFNα/βRonly in dendritic cells | Morbidity, some mortality DENV-2 | [66] |
LysM-Cre+/−CD11c-Cre+/−IFNARfl/fl | IFNα/βRonly in macrophages and dendritic cells | Mortality DENV-2 | [66] |
CD4-Cre+/−IFNARfl/fl | IFNα/βRonly in CD4+ cells | Survival DENV-2 | [66] |
All mouse strains backcrossed to C57BL/6 unless otherwise noted
HLA*IFNAR−/− transgenic mice were sublethally infected and sacrificed to study immune responses.